Jason Rhodes
Founder bij DYNE THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
Jason Rhodes is a partner and focuses on creating and building novel therapeutics companies.
Jason is the chairman and was the founding CEO of Dyne Therapeutics (NASDAQ: DYN), Rectify Pharmaceuticals, and Generation Bio (NASDAQ: GBIO).
He is also on the boards of AAVantgarde Bio, Be Biopharma, K36, and Accent Therapeutics.
He was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020, and was previously on the boards of Third Harmonic Bio (NASDAQ: THRD), Replimune (NASDAQ: REPL), and Bicycle Therapeutics (NASDAQ: BCYC).
Previously, Jason held leadership positions at Alnylam Pharmaceuticals (NASDAQ: ALNY), where he led business development, and Epizyme (NASDAQ: EPZM), where he was President and built the company from early stage research into the clinic and through a successful IPO in 2013.
Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer.
Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
Jason spends his free time mountain biking and loudly watching Spanish fútbol with his family.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
DYNE THERAPEUTICS INC
-.--% | 24-05-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
GENERATION BIO CO.
-.--% | 08-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Jason Rhodes
Bedrijven | Functie | Begin |
---|---|---|
GENERATION BIO CO. | Founder | 01-01-2016 |
DYNE THERAPEUTICS, INC. | Founder | 01-12-2017 |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Director/Board Member | 01-01-2016 |
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Founder | - |
AAVantgarde Bio Srl
AAVantgarde Bio Srl Miscellaneous Commercial ServicesCommercial Services AAVantgarde Bio Srl is a clinical stage biotechnology start-up based in Milan, Italy. The Italian company has developed proprietary adeno-associated viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at TIGEM (Telethon Institute of Genetics and Medicine), AAVantgarde's platforms are focused on broadening the application of AAV-based therapies by addressing the limitations of single AAV therapies cargo capacity. Natalia Misciattelli has been the CEO of the company since 2022. | Director/Board Member | - |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Director/Board Member | - |
Rectify Pharmaceuticals LLC
Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Chairman | - |
Be Biopharma, Inc.
Be Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Be Biopharma, Inc. develops engineered B cells as a new category of cellular medicines. The company was founded by David Steinberg, Aleks Radovic-Moreno and Lea Hachigian and is headquartered in Cambridge, MA. | Director/Board Member | - |
Accent Therapeutics, Inc.
Accent Therapeutics, Inc. BiotechnologyHealth Technology Accent Therapeutics, Inc. operates as a biopharmaceutical company which develops treatments for cancer patients. The company was founded by Howard Y. Chang, Chuan He and Robert A. Copeland in September 2017 and is headquartered in Lexington, MA. | Director/Board Member | 01-01-2017 |
░░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Eerdere bekende functies van Jason Rhodes
Bedrijven | Functie | Einde |
---|---|---|
░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Jason Rhodes
Yale University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 6 |
---|---|
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
BICYCLE THERAPEUTICS PLC | Health Technology |
REPLIMUNE GROUP, INC. | Health Technology |
GENERATION BIO CO. | Health Technology |
DYNE THERAPEUTICS, INC. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
Bedrijven in privébezit | 16 |
---|---|
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
Zyngenia, Inc.
Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Retail Trade |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
New England Venture Capital Association, Inc.
New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | Commercial Services |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Finance |
Raze Therapeutics, Inc.
Raze Therapeutics, Inc. BiotechnologyHealth Technology Raze Therapeutics, Inc. engages in the discovery and development of oncology therapeutics. It offers a pipeline of one-carbon (1C) metabolism therapeutics across solid and hematologic cancers, including genetically-defined cancers. The company was founded by Vamsi Mootha, Joshua Rabinowitz, David Sabatini, and Adam Friedman on August 8, 2014 and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Life Science Advisors LLC
Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
Accent Therapeutics, Inc.
Accent Therapeutics, Inc. BiotechnologyHealth Technology Accent Therapeutics, Inc. operates as a biopharmaceutical company which develops treatments for cancer patients. The company was founded by Howard Y. Chang, Chuan He and Robert A. Copeland in September 2017 and is headquartered in Lexington, MA. | Health Technology |
Be Biopharma, Inc.
Be Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Be Biopharma, Inc. develops engineered B cells as a new category of cellular medicines. The company was founded by David Steinberg, Aleks Radovic-Moreno and Lea Hachigian and is headquartered in Cambridge, MA. | Commercial Services |
Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Rectify Pharmaceuticals LLC
Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Commercial Services |
AAVantgarde Bio Srl
AAVantgarde Bio Srl Miscellaneous Commercial ServicesCommercial Services AAVantgarde Bio Srl is a clinical stage biotechnology start-up based in Milan, Italy. The Italian company has developed proprietary adeno-associated viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at TIGEM (Telethon Institute of Genetics and Medicine), AAVantgarde's platforms are focused on broadening the application of AAV-based therapies by addressing the limitations of single AAV therapies cargo capacity. Natalia Misciattelli has been the CEO of the company since 2022. | Commercial Services |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Health Technology |